Thromboprophylaxis Following Hip and Knee Surgery
| Autor: | Lilia Panamsky, Sarah Gomes, Elizabeth McAuley, Wilma Hopman, Kristen Marosi, Siddhartha Srivastava |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Canadian Journal of General Internal Medicine. 17:33-40 |
| ISSN: | 2369-1778 1911-1606 |
| DOI: | 10.22374/cjgim.v17i3.592 |
| Popis: | Objective: We aimed to describe the current pharmacologic thromboprophylaxis practice after total hip arthroplasty (THA) and total knee arthroplasty (TKA) at a tertiary care center in Canada. Methods: A retrospective cohort study was conducted on patients following elective arthroplasty or fracture surgery between March 1, 2019 and March 31, 2020. The primary outcome was the rate of use of different anti-thrombotic medications. Secondary outcomes included duration of antithrombotic therapy, adherence to major international guidelines, 30-day venous thromboembolism (VTE) incidence, and bleeding complications. Results: Over 98% of patients were prescribed pharmacoprophylaxis in hospital and on discharge. Inpatient VTE prophylaxis was predominantly dalteparin (64.5%) and aspirin (ASA; 34.1%) for THA, and dalteparin (65.5%) and ASA (33.1%) for TKA. Discharge prescriptions had dalteparin (60.2%) and ASA (36.9%) for THA compared to ASA (56.5%), dalteparin (28.2%), and combined dalteparin with ASA (12.3%) for TKA. There was minimal use of direct oral anticoagulants (DOAC) in either type of surgery ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|